Epimmune Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (1997)
Status: Acquired by IDM Pharma (2005) → now Takeda (2009)

Organization Overview

First Clinical Trial
2003
NCT00054899
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Pharmexa-Epimmune

Active Ingredients

Drugs in Phase 2 Trials (2)

ep-2101 (3 trials)

incomplete freund's adjuvant (1 trial)

Drugs in Phase 1 Trials (3)

ep1090 (1 trial)

ep-1233 (1 trial)

mva-mbn32 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colonic Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 1)

HIV Infections (Phase 1)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5